TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Phone+1-919-7658400
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
OptionableOptionable
TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions
What is TransEnterix's stock symbol?
TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."
How were TransEnterix's earnings last quarter?
TransEnterix, Inc. (NYSEAMERICAN:TRXC) posted its quarterly earnings data on Thursday, November, 8th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.07) by $0.01. The medical instruments supplier earned $5.40 million during the quarter, compared to analyst estimates of $5.40 million. The company's revenue for the quarter was up 2850.8% on a year-over-year basis. View TransEnterix's Earnings History.
When is TransEnterix's next earnings date?
What guidance has TransEnterix issued on next quarter's earnings?
TransEnterix issued an update on its FY 2018 earnings guidance on Monday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $24-24 million, compared to the consensus revenue estimate of $23.89 million.TransEnterix also updated its Q4 2018 guidance to EPS.
What price target have analysts set for TRXC?
3 brokerages have issued 12 month price targets for TransEnterix's shares. Their forecasts range from $5.00 to $5.50. On average, they anticipate TransEnterix's share price to reach $5.25 in the next twelve months. This suggests a possible upside of 88.2% from the stock's current price. View Analyst Price Targets for TransEnterix.
What is the consensus analysts' recommendation for TransEnterix?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TransEnterix.
What are Wall Street analysts saying about TransEnterix stock?
Here are some recent quotes from research analysts about TransEnterix stock:
- 1. According to Zacks Investment Research, "TransEnterix Inc. designs, develops and manufactures medical-devices. It offers SPIDER(R) Surgical System, a laparoscopic surgical platform that allows intra-abdominal triangulation procedures to be performed with articulating instruments through a single site. The company is primarily focused on the development and commercialization of SurgiBot, a patient-side minimally invasive surgical robotic system. TransEnterix Inc., formerly known as SafeStitch Medical, Inc., is based in United States. " (1/11/2019)
- 2. BTIG Research analysts commented, "with TransEnterix announced the acquisition of MST Israeli company that has created an image analytics technology that uses artificial intelligence, scene recognition, and machine learning. With the cash + stock transaction (worth ~$33M as of 9/21 closing price) expected to close in Q4, TRXC will pick up the IP portfolio (30 patents, 31 pending), technology assets, and MST’s employees. Though the co’s AutoLap platform has FDA 510(k) and CE Mark clearance, TRXC does not intend to sell it as a standalone product. Instead, its capabilities— including dynamic 3D digital measurement, auto zoom, and anatomical structure identification—will be integrated into Senhance. Timing for these enhancements is unclear, though it is likely to take quarters, not years. We see this as an exciting step toward advanced digital laparoscopy, but our near-term focus remains on system sales." (9/25/2018)
Has TransEnterix been receiving favorable news coverage?
News headlines about TRXC stock have trended extremely positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. TransEnterix earned a coverage optimism score of 4.1 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Are investors shorting TransEnterix?
TransEnterix saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 36,359,091 shares, a decrease of 5.0% from the December 14th total of 38,257,676 shares. Based on an average trading volume of 4,036,364 shares, the short-interest ratio is presently 9.0 days. Approximately 20.4% of the shares of the company are short sold. View TransEnterix's Current Options Chain.
Who are some of TransEnterix's key competitors?
Some companies that are related to TransEnterix include Advanced Medical Solutions (AMS), Akers Biosciences (AKR), Ansell (ANN), ANSELL LTD/S (ANSLY), Bovie Medical (BVX), Bovie Medical (BVX), Clover (CLV), CONVATEC GRP PL/ADR (CNVVY), CRH Medical (CRHM), CRH Medical (CRH), Daxor (DXR), Enerplus (ERF), Essilor International Cmgn Gnl D Optq (EI), Gerresheimer (GXI) and InfuSystem (INFU).
Who are TransEnterix's key executives?
TransEnterix's management team includes the folowing people:
- Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
- Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
- Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
- Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
- Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)
Who are TransEnterix's major shareholders?
TransEnterix's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.05%). Company insiders that own TransEnterix stock include Anthony C J Fernando, Joseph P Slattery, Richard C Pfenniger Jr, Todd Pope, Willam N Kelley and William N Starling Jr. View Institutional Ownership Trends for TransEnterix.
Which major investors are buying TransEnterix stock?
TRXC stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought TransEnterix stock in the last two years include Richard C Pfenniger Jr and Willam N Kelley. View Insider Buying and Selling for TransEnterix.
How do I buy shares of TransEnterix?
Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TransEnterix's stock price today?
One share of TRXC stock can currently be purchased for approximately $2.79.
What is TransEnterix's official website?
How can I contact TransEnterix?
TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.
MarketBeat Community Rating for TransEnterix (NYSEAMERICAN TRXC)
MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote "Outperform" if you believe TRXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
